Explore vital drug delivery innovations at online event
The readers of Outsourcing-Pharma are keenly interested in the latest drug delivery developments—it’s one of the topics visitors to our website most often search for. Industry professionals know they must keep apprised of the latest discoveries, enhancements to current methods, dosage issues, bioavailability concerns, and other vital matters.
To satisfy their curiosity (and to help them remain competitive in today’s dynamic market), OSP and its sister publication BioPharma-Reporter are presenting a free online event Innovations in Drug Delivery, this Wednesday at 10 am CST. Our editors will be welcoming four leading experts, each bringing a wealth of knowledge and record of innovation, to share their insights during this hour-long event—register today to take part in this fascinating, important webinar.
Here are the four organizations that will be represented by the knowledgeable speakers:
AstraZeneca
Annette Bak is head of advanced drug delivery in pharmaceutical sciences R&D at the global pharmaceutical firm. In her position, she reportedly has been instrumental in delivering new modality formulations for clinical studies, most notably vascular endothelial growth factor (VEGF) mRNA currently evaluated for cardiac regeneration, building intracellular drug delivery capabilities, and sponsoring initiatives on augmenting drug discovery with AI.
During her presentation, Bak will be discussing innovations in gene therapy drug delivery, including the use of nanoparticle technology to get large molecules into the cell (a non-viral vector approach).
Graz University of Technology
Sven Stegemann is professor for patient-centric drug product development at Graz University of Technology in Austria. During a career that spans over nearly three decades, he has advised pharma firms on ways to improve formulation design, development, and manufacture of pharmaceutical products, including advanced drug delivery and manufacturing technologies and controls. He will be discussing drug delivery developments to date, emerging trends, and challenges.
i20 Therapeutics
Ravi Srinivasan is CEO and co-founder of i2O Therapeutics, an organization whose mission is to develop oral biologics. He will discuss the development of safe and effective oral formulations of therapies traditionally limited to injections.
Srinivasan reportedly has a track record in leading companies from inception to exit and developing products from concept through commercialization. His therapeutic areas of interest and experience are oncology, dermatology, ophthalmology, and diabetes.
The University of Texas at Austin
Robert O. Williams III is professor in the division of molecular pharmaceutics and drug delivery head at the College of Pharmacy at the University of Texas at Austin. His lab’s research focuses on efforts to enhance solubility and dissolution via novel particle engineering technologies.
In 2019, the National Academy of Inventors named him a fellow for his body of work. He will be talking about a thin film freezing (TFF) platform, which is designed to turn more molecules into inhalable therapies.
After the four speakers have presented, the experts will field questions submitted by attendees. For more information or to register for this free event, visit the Innovations in Drug Delivery webpage.
